SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF, a New Plateau
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (1483)10/24/2002 1:14:53 PM
From: tuck  Read Replies (2) of 2243
 
Rick,

Given news about MEDI-507 causing immunogenicity in half the patients, do you think MEDI might (finally) be more open to lower doses in the retrials as suggested by Dumont's data?

Message 17203796

ncbi.nlm.nih.gov

If so, maybe BTRN would be a buy if/when MEDI goes that way, or if they return the rights to BTRN and BTRN goes that way (of course, where are they going to get the money).

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News